These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20578819)

  • 1. Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
    Ngo BT; Felthaus J; Hein M; Follo M; Wider D; Ihorst G; Engelhardt M; Wäsch R
    Leuk Lymphoma; 2010 Sep; 51(9):1632-42. PubMed ID: 20578819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualizing cancer therapy.
    Gertz MA; Tadmor T
    Leuk Lymphoma; 2010 Sep; 51(9):1585-7. PubMed ID: 20578822
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
    Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
    Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
    Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
    Karlin L; Soulier J; Chandesris O; Choquet S; Belhadj K; Macro M; Bouscary D; Porcher R; Ghez D; Malphettes M; Asli B; Brouet JC; Bories JC; Hermine O; Fermand JP; Arnulf B
    Leuk Lymphoma; 2011 Feb; 52(2):238-46. PubMed ID: 21261498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
    Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
    Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
    Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
    Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
    Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
    Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
    Mateos-Mazon J; Pérez-Simón JA; Lopez O; Hernández E; Etxebarria J; San Miguel JF
    Haematologica; 2007 Sep; 92(9):1295-6. PubMed ID: 17768136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor for treatment of multiple myeloma.
    Ahmad K
    Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.